374 related articles for article (PubMed ID: 28007776)
1. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
Balli D; Rech AJ; Stanger BZ; Vonderheide RH
Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
[No Abstract] [Full Text] [Related]
2. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
3. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
6. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
7. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
8. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
9. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
Mirlekar B; Michaud D; Searcy R; Greene K; Pylayeva-Gupta Y
Cancer Immunol Res; 2018 Sep; 6(9):1014-1024. PubMed ID: 29980536
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
11. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
[TBL] [Abstract][Full Text] [Related]
12. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
13. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
[No Abstract] [Full Text] [Related]
14. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
Fearon DT
Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
[TBL] [Abstract][Full Text] [Related]
15. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
16. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Hulbert A; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2017 Nov; 5(11):978-991. PubMed ID: 29066497
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
[TBL] [Abstract][Full Text] [Related]
19. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
[TBL] [Abstract][Full Text] [Related]
20. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
